Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial

Journal of Rheumatology

Volumn 39, Issue 8, 2012, Pages 1632-1640

  Chatham, W Winn ^a   Wallace, Daniel J ^b   Stohl, William ^c   Latinis, Kevin M ^d   Manzi, Susan ^e   McCune, W Joseph ^f   Tegzová, Dana ^g   McKay, James D ^h   Avila Armengol, Hilario E ⁱ   Utset, Tammy O ^j   Zhong, Z John ^k   Hough, Douglas R ^k   Freimuth, William W ^k   Migone, Thi Sau ^k  

^a University of Alabama at Birmingham   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c LAC USC MEDICAL CENTER   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^h Oklahoma Center for Arthritis Therapy and Research   (United States)

ⁱ Instituto Jalisciense de Investigacion Clinica   (Mexico)

^j UNIVERSITY OF CHICAGO   (United States)

^k GLAXOSMITHKLINE   (United States)

more..

Author keywords

Belimumab; Influenza; Pneumococcus; Systemic lupus erythematosus; Tetanus; Vaccine

Indexed keywords

ANTIBODY; AZATHIOPRINE; BELIMUMAB; INFLUENZA VACCINE; METHOTREXATE; MYCOPHENOLIC ACID; PLACEBO; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; FEMALE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; TETANUS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA VACCINES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; TETANUS TOXOID;

EID: 84864539854     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111587     Document Type: Article

References (19)

1. O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: A review of effectiveness and safety. Lupus 2006;15:778-83.
2. Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Boutin-Le Thi Huong D, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum 2011;63:3502-11.
3. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
4. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
5. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192:953-64.
6. Harless SM, Lentz VM, Sah AP, Hsu BL, Clise-Dwyer K, Hilbert DM, et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 2001;11:1986-9. (Pubitemid 33146427)
7. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis family and B lymphocyte stimulator. Science 1999;285:260-3. (Pubitemid 29330000)
8. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65. (Pubitemid 37409340)
9. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012 Jan 24 (E-pub ahead of print).
10. Galazka AM. The immunological basis for immunization series. Module 3: Tetanus. Geneva: World Health Organization; 1993. [Internet. Accessed May 3, 2012.] Available from: http://www.who.int/vaccines-documents/DocsPDF-IBI-e/mod3- e.pdf
11. World Health Organization. Immunizations, vaccines and biologicals: Pneumococcal vaccines. 2003. [Internet. Accessed May 3, 2012.] Available from: http://www.who.int/vaccines/en/pneumococcus.shtml
12. World Health Organization. Initiative for vaccine research (IVR). Acute respiratory infections. Influenza. 2009. [Internet. Accessed May 3, 2012.] Available from: http://www.who.int/vaccine-research/diseases/ari/en/index1. htmlresearch/diseases/ari/en/index1.html
13. Treanor J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev Bio 2003;115:97-104.
14. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78.
15. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1997;46:1-24.
16. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011;29:1643-8.
17. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010;39:442-7.
18. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Håwi G, Bokarewa M. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 2010;12:R111.
19. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75-81.